Referred to the House Committee on Energy and Commerce.
This bill expands federal price-transparency requirements for hospitals and health plans. Hospitals must publish machine-readable lists of standard charges, payer-specific negotiated rates, de-identified min/max negotiated charges, discounted cash prices, billing codes, and provide online price-estimator tools covering at least 300 shoppable services.
Progressives emphasize consumer empowerment and drug price transparency.
Relative to its intended legislative type, this bill is a substantive policy change that is well-specified in the required disclosures, formats, and definitions and integrates cleanly into existing statutory structures.
This bill expands federal price-transparency requirements for hospitals and health plans.
Hospitals must publish machine-readable lists of standard charges, payer-specific negotiated rates, de-identified min/max negotiated charges, discounted cash prices, billing codes, and provide online price-estimator tools covering at least 300 shoppable services.
The bill amends ACA transparency rules to require in-network rates, out-of-network allowed amounts, negotiated drug rates, and historical net drug prices be disclosed through internet self-service tools and paper requests.
Likely to attract bipartisan interest on transparency but faces substantial industry pushback, legal complexity, and Senate hurdles.
Relative to its intended legislative type, this bill is a substantive policy change that is well-specified in the required disclosures, formats, and definitions and integrates cleanly into existing statutory structures. It provides clear mechanism-level detail but omits implementation timelines, funding provisions, and comprehensive accountability/audit mechanisms.
Progressives emphasize consumer empowerment and drug price transparency.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize consumer empowerment and drug price transparency.
Generally supportive because the bill increases consumer access to pricing data and drug price transparency.
Sees potential to reduce surprise bills and improve accountability, but may worry about weak enforcement and possible hospital gaming.
Cautiously favorable: values consumer information but concerned about implementation, accuracy, and administrative costs.
Supports phased, well-specified standards to avoid confusion and undue burden on providers and plans.
Skeptical: supports greater market information in principle but worries about federal overreach and damage to negotiated contracting.
Sees risks to competition and proprietary negotiation leverage and dislikes mandates on self-insured plans.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Likely to attract bipartisan interest on transparency but faces substantial industry pushback, legal complexity, and Senate hurdles.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize consumer empowerment and drug price transparency.
Likely to attract bipartisan interest on transparency but faces substantial industry pushback, legal complexity, and Senate hurdles.
Relative to its intended legislative type, this bill is a substantive policy change that is well-specified in the required disclosures, formats, and definitions and integrates cleanly into existing statutory structures.…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.